Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial

BACKGROUND: We conducted an open-label, randomized controlled trial evaluating the appropriate treatment duration of leuprorelin acetate 3-month depot, TAP-144-SR (3M), administered postsurgically every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen, for 5 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohashi, Yasuo, Shiba, Eiichi, Yamashita, Hiroko, Kurebayashi, Junichi, Noguchi, Shinzaburo, Iwase, Hirotaka, Yoshida, Michihiro, Fujimoto, Tsukasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785605/
https://www.ncbi.nlm.nih.gov/pubmed/29063390
http://dx.doi.org/10.1007/s00520-017-3914-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785605/
https://www.ncbi.nlm.nih.gov/pubmed/29063390
http://dx.doi.org/10.1007/s00520-017-3914-2

Ejemplares similares